Across the United States and beyond, a fierce policy debate is unfolding over how to regulate kratom, the Southeast Asian tree whose leaves have been used for generations as a mild stimulant and folk remedy. At the center of that debate is 7-hydroxymitragynine, or 7-OH, a powerful alkaloid that can be isolated or synthesized and then marketed in products that look like kratom but behave far more like a conventional opioid.
To understand why lawmakers, regulators and consumer advocates increasingly argue that natural kratom should remain legal while synthetic 7-OH products face bans, it helps to begin with the plant itself. Kratom, or Mitragyna speciosa, contains dozens of alkaloids, chiefly mitragynine, which at typical serving sizes is associated with stimulating or mood-lifting effects and, at higher amounts, more sedating properties. Public health reviews have noted that traditional kratom use in Southeast Asia has spanned decades, often among laborers who chew fresh leaves or drink teas, with patterns of harm that differ markedly from those seen with modern, high-potency 7-OH concentrates.
By contrast, 7-OH is a more potent metabolite of mitragynine that has become the focal point of regulatory action. Laboratory and animal studies suggest that 7-OH binds to opioid receptors more strongly than mitragynine and may be several times more potent than morphine by weight, dramatically increasing the risk of dependence, respiratory depression and other opioid-like adverse effects. Treatment centers and addiction specialists have reported that people using 7-OH–heavy products, especially labeled “enhanced kratom” or similar, can develop tolerance and withdrawal symptoms in a matter of days, in some cases requiring opioid-style detox protocols and medication-assisted treatment.
The U.S. Food and Drug Administration (FDA) has moved to draw a clearer line between the plant and its most powerful derivative. In a 2025 enforcement announcement, the agency stated that 7-OH is not approved as a drug for any indication, is not lawful in dietary supplements and cannot be legally added to conventional foods, describing it as an opioid-like substance with clear abuse potential. In the same communication, the FDA emphasized that its actions targeted concentrated 7-OH products, often sold in vapes, shots and capsules, and explicitly noted that these steps did not extend to traditional leaf kratom products, which have shown a different safety profile in observational data and controlled tolerability studies.
That distinction has been echoed in emerging policy analyses. A recent report from the Drug Enforcement and Policy Center at The Ohio State University’s Moritz College of Law outlined how state-level regulators are being urged to focus on synthetic kratom compounds and other chemically altered derivatives, rather than banning the natural plant outright. In Ohio, Governor Mike DeWine asked the state Board of Pharmacy through an executive action to “immediately designate all synthetic kratom compounds and other dangerous compounds derived from the active ingredient in kratom as illegal drugs,” while the board prepared separate rules that could place both natural and synthetic kratom into Schedule I, sparking intense public testimony from consumers and advocates who fear that conflating leaf and synthetic products will drive the trade underground.
These policy moves are occurring alongside a broader push for consumer protections. Some states have considered or adopted versions of the Kratom Consumer Protection Act, model legislation that aims to keep natural kratom legal while imposing age limits, labeling standards and testing requirements to keep out adulterants, including synthetic 7-OH and other undisclosed substances. Health policy organizations note that such frameworks are designed to address a key problem in the supplement market: products labeled as “kratom” that in reality contain concentrated or synthetic 7-OH in doses far beyond what would occur naturally in leaf powder.
Medical voices have also weighed in on the distinction. In an article for Pharmacy Times, clinicians argued that synthetic, concentrated 7-OH products pose significant risks and should be scheduled as controlled substances, whereas natural leaf kratom, when used responsibly, appears to carry a far lower risk profile. The piece highlighted recent FDA-sponsored clinical research in which volunteers consumed up to 12 grams of kratom leaf powder—roughly four times a typical U.S. serving—without serious safety signals, a finding the authors said supported the idea that whole-leaf preparations and 7-OH concentrates should not be regulated as if they were the same substance.
Academic researchers are adding nuance to this picture by examining how 7-OH actually appears in the body. A 2025 review published in the National Institutes of Health’s open-access journal platform traced the evolution of kratom research from early ethnobotanical accounts to modern pharmacology, noting that fresh kratom leaves contain little to no measurable 7-OH, which instead forms largely as a metabolite when mitragynine is processed in the body. That means natural kratom products deliver a complex mixture of alkaloids that the liver gradually converts, while synthetic or highly concentrated 7-OH formulations bypass that slower pathway and deliver a direct, powerful opioid receptor stimulus.
Public health experts warn that this difference in pharmacology has real-world consequences. Treatment facilities and wellness centers have reported cases in which individuals believed they were using “natural kratom” but were, in fact, consuming gummies, shots or powders spiked with 7-OH or other potent additives, leading to rapid onset dependence, severe withdrawal and in some instances overdose. Recovery clinicians describe these products as having far more in common with illicit opioids than with the traditional kratom teas used in rural Southeast Asia, and argue that packaging them under the kratom umbrella misleads consumers and complicates the work of emergency physicians.
Yet even as these risks become clearer, the policy conversation remains complex. Some critics of kratom point to poison control data and case reports that do not always distinguish between natural leaf products and synthetic or enhanced formulations, making it difficult for lawmakers to calibrate their response. Advocates counter that when cases are broken down, severe outcomes are disproportionately linked to products that contain elevated levels of 7-OH, other opioids or adulterants, rather than plain kratom leaf powder sold with transparent labeling and third-party testing.
International context adds another layer to the argument. In Thailand, where kratom grows natively and has been used for decades, recent reforms have decriminalized the plant under certain conditions while still prohibiting products that resemble conventional narcotics. Officials there have described a harm-reduction approach that seeks to differentiate between a culturally embedded leaf and modern high-potency extracts. That model is increasingly cited by kratom policy advocates in the United States as evidence that regulatory systems can draw a line between natural and synthetic without resorting to outright bans on the plant itself.
Industry groups and consumer organizations are now urging regulators to codify that line in law. They argue that banning synthetic 7-OH and similar derivatives while keeping natural kratom legal, with robust testing and labeling standards, would align policy with current science and reduce the incentive for bad actors to flood the market with unregulated, ultra-potent products. Without that distinction, they warn, lawmakers risk pushing responsible kratom consumers toward illicit markets or more dangerous substances, undermining the public health goals that these regulations aim to achieve.
What emerges from this debate is not a simple narrative of a safe plant and a dangerous chemical, but a more intricate story about how modern manufacturing and marketing have transformed a traditional herb into a new class of quasi-opioid products. As evidence accumulates, a growing chorus of researchers, clinicians and policymakers is calling for a targeted crackdown on synthetic and concentrated 7-OH, coupled with carefully designed protections for natural kratom. Whether legislators adopt that nuanced approach may determine not just the future of kratom, but the broader template for regulating powerful compounds that originate in plants yet behave, in human hands, very differently from the leaves on the tree.